Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Gene One Life Science to repurchase KRW 2.6 billion of debt early on bondholder put option exercise

Gene One Life Science to repurchase KRW 2.6 billion of debt early on bondholder put option exercise

BitgetBitget2026/10/07 10:02

Gene One Life Science set an early repurchase of KRW 2.5 billion of its 6th private convertible bonds. Total cash outlay set at KRW 2.6 billion, reflecting principal and interest; payment scheduled for Nov. 4, 2026. Transaction triggered by a bondholder put option; repurchase to be funded from internal cash. Bonds carry a conversion price of KRW 10,960; full conversion would issue 228,102 common shares, equal to 1.25%. Outstanding principal balance expected to fall to KRW 500 million following the buyback. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gene One Life Science Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261007000497), on October 07, 2026, and is solely responsible for the information contained therein.

  • Gene One Life Science set an early repurchase of KRW 2.5 billion of its 6th private convertible bonds.
  • Total cash outlay set at KRW 2.6 billion, reflecting principal and interest; payment scheduled for Nov. 4, 2026.
  • Transaction triggered by a bondholder put option; repurchase to be funded from internal cash.
  • Bonds carry a conversion price of KRW 10,960; full conversion would issue 228,102 common shares, equal to 1.25%.
  • Outstanding principal balance expected to fall to KRW 500 million following the buyback.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gene One Life Science Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261007000497), on October 07, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Cramer Most Bearish on Stock Plummeting 61%: Intel (INTC.US) Lowers Guidance Amid Executive Stock Purchases

Jim Cramer called Intel his top stock pick, but its share price is down about 61% from its historical high. Intel lowered its Q4 revenue guidance to below $16.5 billion. CEO Pat Gelsinger recently bought 150,000 additional shares. Meanwhile, a shareholder lawsuit accuses the company of underestimating the weakness in the PC market.

智通财经•2026/11/17 03:51
Cramer Most Bearish on Stock Plummeting 61%: Intel (INTC.US) Lowers Guidance Amid Executive Stock Purchases

Chevron (CVX.US) Nears Acquisition of Blackstone's Beacon Offshore, Expanding its Gulf of Mexico Energy Assets

It is reported that Chevron is close to acquiring Beacon Offshore, backed by Blackstone Group, for $5 billion.

智通财经•2026/11/17 02:41
Chevron (CVX.US) Nears Acquisition of Blackstone's Beacon Offshore, Expanding its Gulf of Mexico Energy Assets